UDC 617.735-002-02:616.379-008.64-092.9-085

https://doi.org/10.31288/oftalmolzh201544954

Content of highly toxic metabolites in blood plasma and retina of experimental animals with streptozotocin diabetes upon exposure to lipoic acid and quercetin

О. А. Moroz, PhD in Medical Sciences

Transcarpathian Regional Clinical Hospital named after А. Novak,

ophthalmological department (Uzhgorod, Ukraine)

E-mail: moroz.oleg@gmail.com

Introduction. The relevance of the work lies in studies of the effect of quercetin and lipoate in treatment of experimental diabetes.

Purpose. To examine the content of highly toxic metabolites in blood plasma and retina of experimental animals with streptozotocin diabetes upon exposure to lipoic acid and quercetin

Methods. The studies were conducted on white rats. Experimental animals were divided into four groups: first - control group (14 rats); second - experimental group (14 rats), diabetes without the use of drugs; third - experimental group (12 rats), diabetes, and the use of lipoic acid; fourth - experimental group (15 rats), diabetes, and the use of quercetin. Determination of methylglyoxal and acetoacetate has been produced in the homogenates of retinas and in blood plasma.

Results. When using lipoic acid and quercetin, a significant increase of high-reactive compounds level has been observed in the retina of experimental animals in streptozotocin diabetes.

Conclusion. It has been observed a significant increase of the level of acetoacetate and methylglyoxal in the retina of rats with streptozotocin diabetes that was particularly pronounced 6 months after the beginning of the experiment. High concentrations of methylglyoxal in the retina can be considered as an important pathochemical element of the mechanism of destruction of this visual analyzer structure in diabetes. Administration of lipoic acid and quercetin medicines when modeling streptozotocin diabetes leads to an expressed reduction of methylglyoxal, and acetoacetate concentration in the blood and the retina of experimental animals. 

 

Keywords: streptozotocin diabetes, retina, methylglyoxal, acetoacetate, quercetin, lipoate, experiment

Literature references:

1. Aleksandrovskiy АYa. [Molecular mechanisms of diabetic complications development]. Biochemistry; 1998. v. 63. No. 11. P. 1470 – 1479.

2. AndrushkovaОА, Antonyuk ТN, Turuto ТА.[Teamapproachto treatment ofocularvascularchangesin patients with diabetes mellitus]. Materialsofthe 1 InternationalConference«Contemporary aspects ofvascular endocrine diseases of visual organ». Kyiv, 2000. p. 85.

3. EfimovА, Skorobonskaya Н, Zueva N. [Diabetic neuropathy]. Journal “Medicine of Ukraine”. 2005. No.3. p. 21-25.

4. LeusNF. [Metabolic mechanismsofdevelopmentandprospectsofmedical treatment ofdiabetic retinitis]. Journal of Ophthalmology. 2003. No. 5. p. 75 – 80.

5. Moroz ОА. [Possibility of metabolic adjustment of functional status of retina mitochondria in different development terms of experimental diabetes]. Journal of Ophthalmology. 2014. No. 2. p. 85-91.
Crossref

6.  NasledovА. SPSS computeranalysisinpsychologyandsocialsciences. St. Petersburg, 2005. 416 p.

7.   [New methods ofbiochemical analysis]. Leningrad University Publishers. 1991. 395 p.

8.  Oleynik ТV. [About the possibility of adjustment of the high toxic metabolites level by streptozotocin diabetes]. Journal of Ophthalmology. 2006. No.3 (II) (410). p.56-58.

9. Pavlyuchenko KP, Mogilevskiy SYu, Chuyko AL. [Possibilities of administration of vitamin В6 for diabetic retinitis prevention in experiment]. Filatov readings. Conference proceedings. – 2011. p. 331-332.

10. Pasechnikova NV. [Laser treatment with eyeground pathology] / Pasechnikova NV. Kyiv, R&D enterprise Naukova Dumka Publishers NAS of Ukraine, 2007. 201 p.

11. Barber AJ. [A new view of diabetic retinopathy: a neurodegenerative disease of the eye]. Prog. In Neuro-Psychopharm. & Biol. Psych. 2003. Vol. 27. p. 283 – 290.
Crossref   Pubmed

12. Bergmeyer HU. [Methoden der enzymatischen Analyse]. Herausgegeben von H. U. Bergmeyer. Berlin. 1986. 2220 p.

13.   Berner AK, Brouwers O, Pringle R. [Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology]. Diabetologia.2012. Vol. 55. p. 845-854.
Crossref

14. Brownlee M. [Biochemistry and molecular cell biology of diabetic complications]. Nature. 2001. Vol. 414. p. 813-820.
Crossref

15. Fong DS, Aiello LP, Ferris FL, Klein RK. [Diabetic retinopathy]. Ophthalmol. 2004. Vol. 27. p. 2540-2553.
Crossref

16.  Fosmark DS, Torjesen PA, Kilhovd BK. [Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus]. Metabolism.2006. Vol. 55. p. 232-236.

17. Gardner TW, Antonetti DA, Barber A. [Diabetic retinopathy more than meets the eye]. Surv. Ophthalmol. 2002. Vol. 47. p. S253-S262.

18. Koya D, Jing GL. [Protein kinase C activation and the development of diabetic complications]. Diabetes. 1998. Vol. 47. p. 859-866.

19. Lang GE. [Pharmacological treatment of diabetic retinopathy]. Ophthalmologica. 2007. Vol. 221. №2. p. 112-117.

20. Lorenzi M, Gerhardinger C. [Early cellular and molecular changes induced by diabetes in the retina]. Diabetologia. 2001. Vol. 44. p. 791-804.

21. Mohamed Q, Gillies MC, Wong TY. [Management of diabetic retinopathy]. JAMA. 2007. Vol. 298. №8. p. 902-916.

22. Ola MS, Nawaz MI. [Neurodegeneration and Neuroprotection in Diabetic Retinopathy]. Int. J. Mol. Sci. 2013. Vol. 14. p. 2559-2572.

23. Ola MS, Berkich DA, Xu Y. [Analysis of glucose metabolism in diabetic rat retinas]. Am. J. Physiol. Endocrinol. Metab. 2006. Vol. 290. p. E1057–E1067.

24. Rabbani N, Thornaley PJ. [The Critical Role of Methylglyoxal and Glyoxalase 1 in Diabetic Nephropathy]. Diabetes. 2014. Vol. 63. p.50-52.

25. Speicher MA, Danis RP, Criswell M. [Pharmacologic therapy for diabetic retinopathy]. Expert Opion Emerg Drugs. 2003. V. 8 (1). p. 239-250.